![]() In a short-term, clinical trial with ABILIFY MAINTENA in patients with schizophrenia treated with gluteal administered ABILIFY MAINTENA, the percent of patients reporting any injection site-related adverse reaction was 5.4%, and 0.6% for placebo. Important Warning and Precaution Regarding Injection Site Reactions Each box of ABILIFY MAINTENA offers needle options for deltoid and gluteal administration-no additional ordering needed.Rotate site of injection between the 2 deltoid or gluteal muscles.Needle options are conveniently color-coded based on the size of patient and site of administration ![]() All doses can be given by deltoid or gluteal intramuscular administration 400 mg and 300 mg doses may be given via the deltoid and gluteal injection sites Dosage adjustments are not recommended for patients with concomitant use of CYP3A4 inhibitors, CYP2D6 inhibitors or CYP3A4 inducers for less than 14 days. Avoid concomitant use of CYP3A4 inducers with ABILIFY MAINTENA for greater than 14 days. Important Warning and Precaution Regarding Concomitant MedicationÄosage adjustments are recommended in patients who are CYP2D6 poor metabolizers and in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14 days. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |